KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Pharmaceutical Sciences / 2020 / Cilt: 17 - Sayı: 5

Formulation and In Vitro Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-Solvent Evaporation Technique

Emülsiyon-Çözücü Buharlaştırma Tekniği ile Hazırlanan Telmisartan Nanopartiküllerinin Formülasyonu ve İn Vitro Değerlendirilmesi

Naile ÖZTÜRK
ASLI KARA
İmran VURAL
Sayfa
492–499
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Sustained release TLM nanoparticles (40% in 24 h) decreased cell viability to 45% for MCF-7 cells at 72 h, even at the lowest TLM concentration, indicating better anticancer efficiency than TLM solution.Conclusion: TLM nanoparticles could be potential anticancer agents for breast cancer and deserve further studies.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:bjectives: Telmisartan (TLM) is an antihypertensive drug that has been shown to have antiproliferative effects on cancer cells.
📊
Temel Bulgular & Veri:TLM-loaded nanoparticles were tested against MCF-7 and MDA-MB-231 breast cancer cell lines for antiproliferative effects.Results: Nanoparticles with mean particle size 272 nm and 79% encapsulation efficiency were obtained.
💡
Sonuç & Katkı:Sustained release TLM nanoparticles (40% in 24 h) decreased cell viability to 45% for MCF-7 cells at 72 h, even at the lowest TLM concentration, indicating better anticancer efficiency than TLM solution.Conclusion: TLM nanoparticles could be potential anticancer agents for breast cancer and deserve further studies.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

bjectives: Telmisartan (TLM) is an antihypertensive drug that has been shown to have antiproliferative effects on cancer cells. It has low solubility and suboptimal oral bioavailability. To investigate the potential anticancer effect of TLM on breast cancer cells, poly (D, L-lactide) (PLA) nanoparticles were formulated with the benefit of improving its solubility.Materials and Methods: TLM-loaded PLA nanoparticles were prepared by emulsion solvent evaporation. The effects of sonication time and polymer:drug ratio on nanoparticle size and drug encapsulation were investigated. TLM-loaded nanoparticles were tested against MCF-7 and MDA-MB-231 breast cancer cell lines for antiproliferative effects.Results: Nanoparticles with mean particle size 272 nm and 79% encapsulation efficiency were obtained. Sustained release TLM nanoparticles (40% in 24 h) decreased cell viability to 45% for MCF-7 cells at 72 h, even at the lowest TLM concentration, indicating better anticancer efficiency than TLM solution.Conclusion: TLM nanoparticles could be potential anticancer agents for breast cancer and deserve further studies.

Abstract

Amaç: Telmisartan (TLM), kanser hücreleri üzerinde antiproliferatif etkisi olduğu gösterilmiş antihipertansif bir ilaçtır. Düşük çözünürlüğe, suboptimal oral biyoyararlanıma sahiptir. TLM’nin meme kanseri hücreleri üzerindeki potansiyel antikanser etkisini araştırmak için, TLM’nin çözünürlüğünü iyileştiren poli (D, L-laktid) PLA nanopartikülleri formüle edilmiştir.Gereç ve Yöntemler: TLM yüklü PLA nanopartikülleri emülsiyon hazırlama-çözücü buharlaştırma yöntemiyle hazırlanmıştır. Sonikasyon süresi ve polimer: ilaç oranının nanopartikül büyüklüğü ve ilaç enkapsülasyonu üzerindeki etkisi araştırılmıştır. TLM yüklü nanopartiküllerin, antiproliferatif etkileri MCF-7 ve MDA-MB-231 meme kanseri hücre hatları kullanılarak test edilmiştir.Bulgular: Ortalama partikül büyüklüğü 272 nm ve %79 enkapsülasyon etkinliğine sahip nanopartiküller elde edilmiştir. Sürekli salım gösteren TLM nanopartikülleri (24 saatte %40) MCF-7 hücrelerinde, TLM çözeltisinden daha iyi antikanser aktivite göstererek, en düşük TLM konsantrasyonunda bile hücre canlılığını 72 saatte %45’e düşürmüştür.Sonuç: TLM nanopartiküllerinin, meme kanseri için potansiyel antikanser ajanlar olabileceği ve daha ileri çalışmalarda araştırılmaya değer olduğu sonucuna varılmıştır.

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, N., KARA, A., VURAL, İ. (2020). Formulation and In Vitro Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-Solvent Evaporation Technique. Turkish Journal of Pharmaceutical Sciences, Cilt: 17 - Sayı: 5, 492–499. https://ajindex.com/articles/403574

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Li J, Chen L, Yu P, Liu B, Zhu J, Yang Y. Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-gamma in human lung adenocarcinoma A549 cells. Molecules. 2014;19:2862-2876.
  2. Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One. 2014;9:e93050. Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, Sano H, Chargui J, Touraine JL, Yoshimura N, Yoshimura R. Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med. 2010;1:301-306.
  3. Kozako T, Soeda S, Yoshimitsu M, Arima N, Kuroki A, Hirata S, Tanaka H, Imakyure O, Tone N, Honda S-I, Soeda S. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio. 2016;6:442-460.
  4. Takahashi S, Uemura H, Seeni A, Tang M, Komiya M, Long N, Ishiguro H, Kubota Y, Shirai T. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate. 2012;72:1559-1572.
  5. Marasini N, Tran TH, Poudel BK, Cho HJ, Choi YK, Chi SC, Choi HG, Yong CS, Kim JO. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Int J Pharm. 2013;441:424-432.
  6. Zhong L, Zhu X, Luo X, Su W. Dissolution properties and physical characterization of telmisartan-chitosan solid dispersions prepared by mechanochemical activation. AAPS PharmSciTech. 2013;14:541-550.
  7. Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, Jonkman JH. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40:1312-1322.
  8. Patel J, Dhingani A, Garala K, Raval M, Sheth N. Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis. Powder Technology. 2014;258:331-343. Meredith PA. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. The American Journal of Cardiology. 1999;84:7-12.
  9. McCall RL, Sirianni RW. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp. 2013:51015. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angi